Key Points
- Insider Shawnte Mitchell sold a total of 40,000 shares on March 3–4 (25,000 at $24.25 and 15,000 at $23.01), generating roughly $951,400 in proceeds per the SEC filing.
- Shares traded down 1.8% to $22.16 on Friday with 210,663 shares changing hands versus an average volume of 1.27M, and the company has a market cap of $1.52B and a 52-week range of $2.86–$36.26.
- Analysts remain generally bullish—nine Buys, one Hold and one Sell—with a consensus "Moderate Buy" and an average price target of $41.78 after multiple firms raised targets.
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Get Free Report) insider Shawnte Mitchell sold 15,000 shares of the company's stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $23.01, for a total value of $345,150.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shawnte Mitchell also recently made the following trade(s):
- On Wednesday, March 4th, Shawnte Mitchell sold 25,000 shares of Olema Pharmaceuticals stock. The shares were sold at an average price of $24.25, for a total value of $606,250.00.
Olema Pharmaceuticals Stock Performance
Shares of NASDAQ OLMA traded down $0.81 during trading hours on Friday, reaching $21.75. The stock had a trading volume of 263,409 shares, compared to its average volume of 1,275,949. The business's fifty day moving average is $25.25 and its two-hundred day moving average is $17.95. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.03 and a quick ratio of 8.03. The company has a market cap of $1.49 billion, a price-to-earnings ratio of -11.63 and a beta of 1.92. Olema Pharmaceuticals, Inc. has a twelve month low of $2.86 and a twelve month high of $36.26.
Hedge Funds Weigh In On Olema Pharmaceuticals
Institutional investors have recently added to or reduced their stakes in the company. Siren L.L.C. acquired a new stake in shares of Olema Pharmaceuticals during the fourth quarter worth approximately $82,518,000. Janus Henderson Group PLC boosted its holdings in shares of Olema Pharmaceuticals by 87.1% in the 4th quarter. Janus Henderson Group PLC now owns 6,710,194 shares of the company's stock worth $167,901,000 after acquiring an additional 3,124,345 shares in the last quarter. Cormorant Asset Management LP bought a new stake in Olema Pharmaceuticals during the 4th quarter worth approximately $68,750,000. RA Capital Management L.P. bought a new stake in Olema Pharmaceuticals during the 4th quarter worth approximately $65,000,000. Finally, Bain Capital Life Sciences Investors LLC raised its position in Olema Pharmaceuticals by 24.3% in the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 8,508,641 shares of the company's stock valued at $212,716,000 after purchasing an additional 1,664,687 shares during the last quarter. 91.78% of the stock is owned by institutional investors.
Analysts Set New Price Targets
OLMA has been the subject of a number of recent research reports. The Goldman Sachs Group increased their price objective on shares of Olema Pharmaceuticals from $26.00 to $38.00 and gave the company a "buy" rating in a research note on Thursday, December 11th. HC Wainwright upped their target price on shares of Olema Pharmaceuticals from $36.00 to $45.00 and gave the company a "buy" rating in a research note on Thursday, December 11th. Stifel Nicolaus initiated coverage on shares of Olema Pharmaceuticals in a research report on Wednesday, February 11th. They issued a "buy" rating and a $48.00 price target for the company. Citigroup raised their price target on shares of Olema Pharmaceuticals from $21.00 to $60.00 and gave the stock a "buy" rating in a research note on Friday, December 12th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Olema Pharmaceuticals in a research note on Thursday, January 22nd. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Olema Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $41.78.
View Our Latest Stock Analysis on OLMA
About Olema Pharmaceuticals
(
Get Free Report)
Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
